Keros Therapeutics (KROS) vs Vanda Pharmaceuticals (VNDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Vanda Pharmaceuticals (VNDA) has outperformed Keros Therapeutics (KROS) over the past year, losing 28.2% versus a loss of 36.3%. Over five years, VNDA leads with a -79.2% price change compared with -80.2% for KROS. Keros Therapeutics is the larger company by market cap ($217.4 million vs $208.3 million), about 1.0 times the size.
Keros Therapeutics converts more of its revenue into profit, with a net margin of 35.7% versus -102.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KROS | VNDA |
|---|---|---|
| Share price | $11.08 | $3.45 |
| Market cap | $217.44M | $208.32M |
| 1-day change | -2.72% | -6.13% |
| YTD return | -45.58% | -60.94% |
| 1-year return | -36.29% | -28.23% |
| 5-year return | -80.25% | -79.18% |
| Forward P/E | — | 17.22 |
| EPS (TTM) | $-2.32 | $-4.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $243.86M | $216.10M |
| Revenue growth (YoY) | — | +8.72% |
| Net income (latest FY) | $87.01M | $-220.47M |
| Gross margin | — | 93.96% |
| Operating margin | 27.71% | -69.95% |
| Net margin | 35.68% | -102.02% |
| 52-week high | $22.55 | $9.94 |
| 52-week low | $8.98 | $3.42 |
| Distance from 52-week high | -50.86% | -65.34% |
| Analyst consensus | buy | none |
| Avg. price target upside | +78.97% | +233.82% |
| Average volume | 196.50K | 1.06M |
| Shares outstanding | 19.62M | 60.47M |
| Employees | 87 | 533 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Keros Therapeutics is more profitable, keeping 35.7 cents of every revenue dollar as net income versus -102.0 cents for Vanda Pharmaceuticals.
About Keros Therapeutics
KROS stock →Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
About Vanda Pharmaceuticals
VNDA stock →Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion.
Health Care · Biotechnology: Pharmaceutical Preparations · 533 employees
KROS vs VNDA FAQ
Which is bigger, Keros Therapeutics or Vanda Pharmaceuticals?
Keros Therapeutics (KROS) is larger, with a market capitalization of $217.44M compared with $208.32M for Vanda Pharmaceuticals (VNDA).
Which stock has performed better over the past year, KROS or VNDA?
VNDA returned -28.23% over the past 12 months, compared with -36.29% for KROS (price return, excluding dividends). Past performance does not predict future results.
Are Keros Therapeutics and Vanda Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.